196 related articles for article (PubMed ID: 30993587)
21. Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY).
Gibb A; Pirrie SJ; Linton K; Warbey V; Paterson K; Davies AJ; Collins GP; Menne T; McKay P; Fields PA; Miall FM; Nagy E; Wheatley K; Reed R; Baricevic-Jones I; Barrington S; Radford J
Br J Haematol; 2021 Apr; 193(1):63-71. PubMed ID: 32926420
[TBL] [Abstract][Full Text] [Related]
22. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.
Horwitz SM; Advani RH; Bartlett NL; Jacobsen ED; Sharman JP; O'Connor OA; Siddiqi T; Kennedy DA; Oki Y
Blood; 2014 May; 123(20):3095-100. PubMed ID: 24652992
[TBL] [Abstract][Full Text] [Related]
23. Brentuximab vedotin in CD30
Enos TH; Feigenbaum LS; Wickless HW
Int J Dermatol; 2017 Dec; 56(12):1400-1405. PubMed ID: 28762479
[TBL] [Abstract][Full Text] [Related]
24. CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies.
Han TH; Gopal AK; Ramchandren R; Goy A; Chen R; Matous JV; Cooper M; Grove LE; Alley SC; Lynch CM; O'Connor OA
J Clin Pharmacol; 2013 Aug; 53(8):866-77. PubMed ID: 23754575
[TBL] [Abstract][Full Text] [Related]
25. Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry.
Bartlett NL; Smith MR; Siddiqi T; Advani RH; O'Connor OA; Sharman JP; Feldman T; Savage KJ; Shustov AR; Diefenbach CS; Oki Y; Palanca-Wessels MC; Uttarwar M; Li M; Yang J; Jacobsen ED
Leuk Lymphoma; 2017 Jul; 58(7):1607-1616. PubMed ID: 27868471
[TBL] [Abstract][Full Text] [Related]
26. Successful treatment with brentuximab vedotin for relapsed and refractory adult T cell leukemia.
Oka S; Ono K; Nohgawa M
Anticancer Drugs; 2020 Jun; 31(5):536-539. PubMed ID: 31934889
[TBL] [Abstract][Full Text] [Related]
27. Poikilodermatous mycosis fungoides with CD30-positive large cell transformation successfully treated by brentuximab vedotin.
Popadic S; Lekic B; Tanasilovic S; Bosic M; Nikolic M
Dermatol Ther; 2020 Jan; 33(1):e13152. PubMed ID: 31743946
[TBL] [Abstract][Full Text] [Related]
28. CD30 is a potential therapeutic target in malignant mesothelioma.
Dabir S; Kresak A; Yang M; Fu P; Wildey G; Dowlati A
Mol Cancer Ther; 2015 Mar; 14(3):740-6. PubMed ID: 25589494
[TBL] [Abstract][Full Text] [Related]
29. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
Younes A; Bartlett NL; Leonard JP; Kennedy DA; Lynch CM; Sievers EL; Forero-Torres A
N Engl J Med; 2010 Nov; 363(19):1812-21. PubMed ID: 21047225
[TBL] [Abstract][Full Text] [Related]
30. Brentuximab-vedotin in combination with cyclophosphamide, doxorubicin, prednisolone for the treatment of aggressive CD30-positive cutaneous T-cell lymphomas.
Ribereau-Gayon E; Donzel M; Pham F; Romain-Scelle N; Perier-Muzet M; Balme B; Traverse-Glehen A; Ghesquières H; Dalle S
Leuk Lymphoma; 2023; 64(8):1424-1432. PubMed ID: 37255021
[TBL] [Abstract][Full Text] [Related]
31. [Ulceration of lymphomatous skin lesions in a patient with Sezary syndrome treated with brentuximab-vedotin].
Maitrepierre F; Schissler C; Cribier B; Lipsker D
Ann Dermatol Venereol; 2020 Mar; 147(3):198-201. PubMed ID: 31959414
[TBL] [Abstract][Full Text] [Related]
32. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies.
Fanale MA; Forero-Torres A; Rosenblatt JD; Advani RH; Franklin AR; Kennedy DA; Han TH; Sievers EL; Bartlett NL
Clin Cancer Res; 2012 Jan; 18(1):248-55. PubMed ID: 22080439
[TBL] [Abstract][Full Text] [Related]
33. Population Pharmacokinetic Modeling and Exposure-Response Assessment for the Antibody-Drug Conjugate Brentuximab Vedotin in Hodgkin's Lymphoma in the Phase III ECHELON-1 Study.
Suri A; Mould DR; Song G; Collins GP; Endres CJ; Gomez-Navarro J; Venkatakrishnan K
Clin Pharmacol Ther; 2019 Dec; 106(6):1268-1279. PubMed ID: 31152605
[TBL] [Abstract][Full Text] [Related]
34. Treatment of mycosis fungoides with brentuximab vedotin: Assessing CD30 expression by immunohistochemistry and quantitative real-time polymerase chain reaction.
Hofer V; Maurus K; Houben R; Schrama D; Roth S; Goebeler M; Geissinger E; Rosenwald A; Wobser M
J Cutan Pathol; 2022 Mar; 49(3):314-317. PubMed ID: 34854114
[No Abstract] [Full Text] [Related]
35. Noninvasive Trafficking of Brentuximab Vedotin and PET Imaging of CD30 in Lung Cancer Murine Models.
Kang L; Jiang D; Ehlerding EB; Barnhart TE; Ni D; Engle JW; Wang R; Huang P; Xu X; Cai W
Mol Pharm; 2018 Apr; 15(4):1627-1634. PubMed ID: 29537283
[TBL] [Abstract][Full Text] [Related]
36. Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30-Expressing Hematologic Malignancies.
Li H; Han TH; Hunder NN; Jang G; Zhao B
J Clin Pharmacol; 2017 Sep; 57(9):1148-1158. PubMed ID: 28513851
[TBL] [Abstract][Full Text] [Related]
37. Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin.
Goyal A; Patel S; Goyal K; Morgan EA; Foreman RK
J Cutan Pathol; 2019 Nov; 46(11):823-829. PubMed ID: 31286556
[TBL] [Abstract][Full Text] [Related]
38. RF - Brentuximab as Treatment for CD30
Morgado-Carrasco D; Combalia A; Estrach Panella T
Actas Dermosifiliogr (Engl Ed); 2019 Nov; 110(9):769-770. PubMed ID: 31151669
[No Abstract] [Full Text] [Related]
39. Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin.
Chihara D; Wong S; Feldman T; Fanale MA; Sanchez L; Connors JM; Savage KJ; Oki Y
Hematol Oncol; 2019 Feb; 37(1):35-38. PubMed ID: 30209819
[TBL] [Abstract][Full Text] [Related]
40. A pilot study of weekly brentuximab vedotin in patients with CD30+ malignancies resistant to brentuximab vedotin every 3 weeks.
Poston JN; Fromm JR; Rasmussen HA; Shustov AR; Libby EN; Smith SD; Gooley T; Gopal AK
Br J Haematol; 2019 Jul; 186(1):159-162. PubMed ID: 30592026
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
